Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or…